Valeant Pharmaceuticals's Earnings Take a Back Seat To Allergan News

Valeant's miss on sales is likely to go almost unnoticed in its pursuit of Allergan

May 11, 2014 at 8:30AM

Canadian health care magpie Valeant (NYSE:VRX) certainly knows how to stay in the spotlight. Investors simply aren't all that interested in quarterly earnings at a time when the company is actively trying to ratchet up the pressure on Allergan (NYSE:AGN) to accept the company's acquisition offer. Valeant continues to look undervalued as it is likely still in the early to-middle years of a debt-fueled grab for scale. However, as the pushback from Allergan shows, not all of the targets Valeant may choose will welcome the company's efforts at empire-building.

Sluggish sales, healthy margins in the first quarter
Valeant reported first quarter earnings on Thursday that saw revenue grow 77%, but miss the average analyst estimates by around 4%. The shortfall appeared to fall pretty evenly across the business, where management reported a "same store" organic growth rate of 1% and a pro forma organic growth rate of 4%. Importantly, the huge Bausch + Lomb business that Valeant acquired in 2013 showed 11% organic revenue growth and 9% growth in the U.S.

What Valeant missed on the top line, it more than recovered through cost control. Gross margin fell more than three points from last year, but surpassed expectations by almost two points. Operating income rose 53%, just barely missing expectations as the operating margin came in a point and a half stronger than the sell-side expected.

Rallying the base to pressure Allergan
Judging by management's comments on the call, they have no intention of giving up their pursuit of Allergan, nor bidding against themselves. Valeant management believes that they have made a compelling offer and, while Allergan's board may not agree, Valeant is looking to address Allergan's shareholders more directly. The exact roadmap is still unclear, but the gist of Valeant's message is that they'll try to marshal Allergan's own shareholders into forcing a referendum or special meeting to consider Valeant's offer.

Allergan is an important asset for Valeant. With its strong position in aesthetics, dermatology, and ophthalmology, there are few assets that offer more strategic synergy. Even allowing that regulators would likely force some product divestitures, Valeant would emerge as a stronger player than Johnson & Johnson in the overall aesthetics market, extend its lead in dermatology, and fill in the sizable gap in its ophthalmology business created by the lack of glaucoma products (glaucoma is about one-third of the ophthalmology drug market).

Tying together $7 billion in Allergan sales with nearly $3 billion in cost synergies and the leverage of a much lower tax rate would make this an exceptionally value-additive deal for Valeant. With that, it's also worth remembering that Valeant is not a crazy bidder. Management has done enough deals to appreciate the sort of synergies it can reasonably expect and the company has shown price discipline in the past (letting Bausch + Lomb outbid for ISTA Pharmaceuticals, for instance).

Is Congress looking to close the door?
There have been increasing rumblings in Washington, D.C. regarding "doing something" about closing the door on future tax inversion deals. The current proposals would make it much harder for an American company to acquire a foreign company and redomicile in a lower-tax region, but current proposals wouldn't seem to have any meaningful impact on companies like Valeant, Actavis, and Endo Health that have already made such moves. Even so, it is not unimaginable to think that the U.S. government may look to alter the rules and force a tighter link between the profits a company earns in the U.S. and the taxes they pay.

The Bottom Line
Should Allergan rebuff Valeant (either by executing a deal of its own or finding another buyer), I believe there are other attractive fish in the sea, including Galderma. Valeant's core growth-by-acquisition model does carry above-average risks from execution/integration, higher rates, and below-normal R&D spending, but Valeant is already well on its way to proving that it can effectively and profitably acquire and market the fruits of other companies' R&D spending.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Valeant Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson and Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers